Reporte zur Charge UT7006NA

Symptomtext

Allergic reaction; hives throughout his face, trunk, legs, and top of feet; Erythema throughout his face, trunk, legs, and top of feet; Initial information regarding an unsolicited valid non-serious case was received from a health care professional via a consumer/non-health care professional via Global Medical Information (Reference number- 00862288) and transmitted to Sanofi on 17-Nov-2021. This case involves a 32 year old male patient who had allergic reaction (hypersensitivity) with associated symptoms hives throughout his face, trunk, legs, and top of feet (urticaria) and erythema throughout his face, trunk, legs, and top of feet (erythema) after receiving INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT]. The patient's medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient had no concomitant vaccination. On 02-Oct-2020, the patient received a 0.5 mL dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (lot UT7006NA and expiry: 30-Jun-2021) via intramuscular route in the left deltoid for prophylactic vaccination. On 02-Oct-2020 the patient developed a non-serious allergic reaction (hypersensitivity) with associated symptoms hives throughout his face, trunk, legs, and top of feet (urticaria) and erythema throughout his face, trunk, legs, and top of feet (erythema) on the same day following the administration of INFLUENZA QUADRIVAL A-B VACCINE. It was reported "Caller states that he had an allergic reaction to the FLUZONE QIV vaccine when he received it on 02-Oct-2020. The symptoms included hives and erythema throughout his face, trunk, legs, and top of feet. The symptoms persisted for 1 week. Caller wanted to know if there was any information available regarding changes made to the FLUZONE QIV vaccine from the 2020 season to the 2021 season so that he could possibly identify what he was allergic to. Caller asked for information on the product composition of FLUZONE QIV from 2019. Caller states that he does not have egg or protein allergies and asked what additional information was available regarding FLUZONE QIV and other types of allergies." No laboratory data was reported. The patient was treated with BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE] and METHYLPREDNISOLONE SODIUM SUCCINATE (SOLUMEDROL) for Hypersensitivity. On an unknown date, the patient had recovered from the event.